Vistagen gets Nasdaq extension to Feb 1, 2027 to cure $1.00 bid price deficiency

Vistagen Therapeutics, Inc.

• Received 180-day extension until February 1, 2027 to regain compliance with Nasdaq minimum bid price of $1.00.
• Previously disclosed non-compliance on February 6, 2026; has not yet cured the deficiency.
• If not compliant by end of Extension Period, Nasdaq will issue delisting notice; company may appeal.
• No assurance that any appeal of a delisting determination would be successful.